Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (567)	12/18/1997 9:50:00 PM
From: Cymeed	Respond to of 887

John, I would say we probably have to forget the law suit stuff. The company is worth of nothing. If a lawsuit is filed, I can see the value of stock approaching zero quickly. The only ones wins in that situation might be the lawers. The shareholders will lose either way. I figure the best thing for me to do is to find out how much this Depo is worth now and what price should I exit. Tomorrow will be low, but holding for a few more days can be even lower or higher. I don't know. If we have a good idea about what the company can do (other drugs, overseas approval, arguing with FDA ?), we may be better prepared this time. Now losing money is for sure, each of us on ths thread need to find the minimal loss.

To: John McCarthy who wrote (567)	12/18/1997 9:52:00 PM
From: Tom D	Read Replies (1) \| Respond to of 887

John, I can give you all of my analysts reports. If you want to pursue it, send me an address by e-mail. If you are thinking class action lawsuit, Bill LeRach or somebody like that will do it, leaving us investors with 5 or 10 cents a share in legal compensation when all is said and done. It is interesting that Ross financial group bought 1 million shares at 14 5/8 a couple months ago. You'd think that they would have had first hand access to the data. This is part of what reassured me. I wonder what they are thinking about their investment in DEPO at this time. Best Regards, Tom D

To: John McCarthy who wrote (567)	12/18/1997 9:59:00 PM
From: John Bloxom	Respond to of 887

<<What is a good first step in obtaining (a) a copy of the clinical trial presented in the newspaper article or Tom's source vs. (b) the trial presented today?>> As a former and sometimes still securities lawyer, your best bet now is: (a) DEPO; and (b) DEPO or, failing that, a Freedom of Information Act Request directed at FDA. My guess is that the company will be glad to oblige. Regards, John

To: John McCarthy who wrote (567)	12/19/1997 12:16:00 AM
From: Andrew H	Respond to of 887

>>What is a good first step in obtaining (a) a copy of the clinical trial presented in the newspaper article or Tom's source vs. (b) the trial presented today?<< John, I think the first thing to do is to listen to or get a comprehensive report from the conference call tomorrow. I think someone posted the number on the thread. I don't really follow the company so I don't know how to get a copy of the trial info you are reuqesting. First I would check with Tom D. and a Baird Soule and a couple of the other more well informed investors on the thread (although in hindsight it appears that no one was very well informed, which may well be the company's fault). Here is the discrepancy--from Tom's post: >>36% of the 25 DepoCyt patients and 17% of the 29 methotrexate patients achieved the primary endpoint, a complete response<< From today's release-- >>An FDA reviewer said there was no real difference found in the number of patients who responded to Depocyte or the standard drug tested in the trial, methotrexate.<< >>Eight of 31 depocyte patients and 6 of 30 methotrexate patients had no worsening of disease, the reviewer said.<< I did notice the average number of survival days in the treated group varied considerably in the IBD article and the passage I qouted from Tom's post. But both looked statistically significant. I would also guess that the IBD article was based on an analyst's report (on data released by the company), so the analysts who cover DEPO must have some of the trial info covered in their reports. Also I would guess the yearly 10K and Annual Report might be good sources of info. I don't know how you could view the data presented to the FDA, but it would certainly be the same P3 trial results they would be looking at. I do remember Tom stating that the trial data was somewhat sketchy and the numbers were low. But he must have gotten past these concerns. What makes this failure even more surprising to me is that there are a number of sharp people on this thread who are not easily bamboozled and generally do good homework. Sorry I can't do more to help.